104 related articles for article (PubMed ID: 21192952)
21. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
22. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
23. [The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].
Xia JS; Chen XG; Zhuang QY; Liu JH; Ye ZQ
Zhonghua Nan Ke Xue; 2009 Jul; 15(7):617-20. PubMed ID: 19694375
[TBL] [Abstract][Full Text] [Related]
24. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Marinov M; Ziogas A; Pardo OE; Tan LT; Dhillon T; Mauri FA; Lane HA; Lemoine NR; Zangemeister-Wittke U; Seckl MJ; Arcaro A
Clin Cancer Res; 2009 Feb; 15(4):1277-87. PubMed ID: 19228731
[TBL] [Abstract][Full Text] [Related]
25. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition.
Michaelis M; Suhan T; Reinisch A; Reisenauer A; Fleckenstein C; Eikel D; Gümbel H; Doerr HW; Nau H; Cinatl J
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3451-7. PubMed ID: 16123451
[TBL] [Abstract][Full Text] [Related]
26. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
27. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
28. [Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation].
Wei F; Zhang P; Qi J; Wang M; Wang G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jan; 30(1):23-7. PubMed ID: 24405594
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M
Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684
[TBL] [Abstract][Full Text] [Related]
30. In human endothelial cells amino acids inhibit insulin-induced Akt and ERK1/2 phosphorylation by an mTOR-dependent mechanism.
Pellegatta F; Catapano AL; Luzi L; Terruzzi I
J Cardiovasc Pharmacol; 2006 May; 47(5):643-9. PubMed ID: 16775502
[TBL] [Abstract][Full Text] [Related]
31. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
Faried LS; Faried A; Kanuma T; Aoki H; Sano T; Nakazato T; Tamura T; Kuwano H; Minegishi T
Mol Carcinog; 2008 Jun; 47(6):446-57. PubMed ID: 18058806
[TBL] [Abstract][Full Text] [Related]
32. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
33. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
35. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
36. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
37. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
[TBL] [Abstract][Full Text] [Related]
38. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
39. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
[TBL] [Abstract][Full Text] [Related]
40. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001.
Yasui H; Naka N; Imura Y; Outani H; Kaneko K; Hamada K; Sasagawa S; Araki N; Ueda T; Itoh K; Myoui A; Yoshikawa H
Cancer Lett; 2014 May; 347(1):114-22. PubMed ID: 24491407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
